CD8A and diffuse large B-cell lymphoma: During recent years, several T-cell-based adoptive immunotherapies have emerged to stimulate and redirect T-cell functions against tumors [45], and the CD8+ T-TIL status was associated with the clinical outcome of DLBCL [46].